ENDRA Life Sciences Inc. NDRA
Biotechnology: Electromedical & Electrotherapeutic Apparatus · IPO 2017 · data as of November 13, 2026
ENDRA Life Sciences Inc. (NDRA) is a healthcare company listed in the US with a market value of about $7M.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -190%.
About ENDRA Life Sciences
ENDRA Life Sciences is listed in the US and classified in biotechnology: electromedical & electrotherapeutic apparatus, IPO year 2017. It was profitable in 0 of the last 10 years in our data. Its share count fell by 73% over three years (buybacks).
Score: 0.6 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 | $0 | $6174 | $351622 | $515582 |
| Net income | -$7M | -$12M | -$10M | -$13M | -$11M | -$12M | -$13M | -$10M | -$5M | -$3M |
| Free cash flow | -$5M | -$7M | -$10M | -$13M | -$11M | -$11M | -$9M | -$8M | -$3M | — |
| EPS (diluted) | $-8.93 | $-56.94 | $-2766.85 | $-4.56 | $-5.55 | $-12.49 | $-46.38 | $-43.01 | $-38.65 | $-76.11 |
| Net margin | — | — | — | — | — | — | — | -158700.0% | -1529.2% | -538.3% |
| ROIC | -165.4% | -344.0% | -173.8% | -169.8% | -96.0% | -153.0% | -198.3% | -144.3% | -87.7% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does ENDRA Life Sciences pay a dividend?
Not currently.
Is ENDRA Life Sciences a good stock to buy?
We do not give buy or sell advice. ENDRA Life Sciences scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.